Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 726-733

John Wiley & Sons Inc

Access to resources Recommend Favorite

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 734-741

John Wiley & Sons Inc

Access to resources Recommend Favorite

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 400-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice

By Schreiber Stephan A.   Russmann Anika  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3131-3136

Informa Healthcare

Access to resources Recommend Favorite

Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 419-426

John Wiley & Sons Inc

Access to resources Recommend Favorite